Cholera Vaccines Market Size & Growth Forecast 2026–2035, By Segments (Type, Distribution Channel, Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Cholera Vaccines Market size was around USD 100.55 Million in 2025 and is slated to grow at a 10.1% CAGR from 2026 to 2035, attaining USD 263.18 Million by 2035. The industry revenue for 2026 is estimated at USD 109.42 million.
Get more details on this report
Request Free Sample ReportCholera Vaccines Market Intelligence Snapshot
Regional Market Dynamics
- North America holds 39.86% share due to strong procurement systems, advanced public health infrastructure, and coordinated vaccine distribution and preparedness frameworks.
- Asia Pacific grows at 11.31% CAGR due to higher outbreak exposure, expanding immunization campaigns, and increasing preventive vaccination in vulnerable populations.
Segment Momentum
- Killed Oral O1 and O139 held a 63% market share in 2025 due to their suitability for large-scale immunization programs, with oral delivery supporting efficient deployment and broad coverage across target populations.
- Retail pharmacy is growing fastest because it expands community-level vaccine access, offering greater convenience and supporting broader distribution beyond hospital-centered immunization pathways.
Market Expansion Drivers
- Increasing cholera outbreak awareness boosting vaccination programs in endemic regions.
- Expanding global travel and NGO-led immunization campaigns driving vaccine demand.
- WHO elimination targets and technology transfer initiatives expanding vaccine production capacity.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Major players in the cholera vaccines market include Sanofi S.A. (France), Valneva SE (France), EuBiologics Co., Ltd. (South Korea), Bharat Biotech International Ltd. (India), Serum Institute of India Pvt. Ltd. (India), Emergent BioSolutions Inc. (United States), Incepta Vaccine Ltd. (Bangladesh), Vabiotech (Vietnam), PT Bio Farma (Persero) (Indonesia), Shantha Biotechnics Pvt. Ltd. (India).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
Rising awareness of recurring cholera outbreaks is prompting health ministries, local agencies, and international partners to move from reactive treatment efforts toward preventive immunization planning, driving demand for the cholera vaccines market. In endemic regions, better surveillance, stronger public health messaging, and more visible links between seasonal outbreaks and sanitation gaps are shaping procurement decisions around pre-emptive stockpiling and targeted community campaigns. This transition supports market expansion by making vaccination a more routine budgeted intervention rather than an emergency-only response, especially in high-risk districts where repeated outbreaks place pressure on already limited health systems.
Expanding global travel and NGO-led immunization campaigns driving vaccine demand
Greater cross-border mobility is increasing attention to cholera exposure risks among travelers, migrant populations, and communities located along trade and displacement corridors, reinforcing market demand for the cholera vaccines market. At the same time, NGO-led immunization campaigns are translating that risk profile into actual vaccine deployment by financing outreach, coordinating last-mile delivery, and supporting rapid campaign execution in fragile or underserved settings. This combination influences market adoption in practice by widening the purchaser base beyond national immunization programs and creating more frequent bulk procurement cycles tied to humanitarian operations, outbreak prevention efforts, and mobile population coverage.
WHO elimination targets and technology transfer initiatives expanding vaccine production capacity
WHO cholera control and elimination goals are pushing manufacturers, donors, and public health institutions to treat supply expansion as a strategic priority, supporting market development in the cholera vaccines market. Technology transfer initiatives play a practical role by enabling additional producers to build manufacturing capability, reduce dependence on a limited supplier pool, and improve the resilience of global vaccine availability. As production capacity broadens, procurement agencies can plan campaigns with greater confidence in supply continuity, which supports larger immunization programs and increases market penetration in countries where rollout has historically been constrained more by availability than by policy intent.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing cholera outbreak awareness boosting vaccination programs in endemic regions | 2.20% | High | Africa, Asia Pacific | High | Near Term |
| Expanding global travel and NGO-led immunization campaigns driving vaccine demand | 1.90% | High | Global | High | Near Term |
| WHO elimination targets and technology transfer initiatives expanding vaccine production capacity | 1.70% | High | Asia Pacific, Africa | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held a 39.86% share of the cholera vaccines market in 2025, supported by established vaccine procurement systems, strong public health infrastructure, and active involvement from government and institutional stakeholders in disease preparedness. The region’s leadership is reinforced by its ability to fund vaccine research, maintain regulated distribution channels, and support stockpiling and immunization planning through coordinated healthcare networks. These practical advantages help sustain steady market activity by improving product availability, procurement efficiency, and deployment readiness.
Asia Pacific is projected to expand at an 11.31% CAGR over the forecast period in the cholera vaccines market, impelled by the region’s higher exposure to cholera outbreaks and the resulting need for broader vaccination coverage. Growth is being accelerated by rising public health attention to outbreak control, expanding immunization efforts in vulnerable populations, and greater adoption of preventive vaccination in areas where sanitation and clean water access remain uneven. In practice, these conditions translate into stronger demand for vaccine supply, wider campaign implementation, and more consistent uptake across at-risk communities.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Quality Manufacturing FocusGermany supports the cholera vaccines market through advanced pharmaceutical manufacturing standards and investments in vaccine quality and regulatory compliance. German organizations also participate in collaborative research and international health programs that strengthen vaccine availability.
France 🇫🇷
Humanitarian Vaccine SupportFrance maintains a strong focus on cholera vaccines through public health collaborations and participation in international immunization initiatives. French organizations contribute to vaccine research and procurement activities that reinforce access for outbreak response programs.
Italy 🇮🇹
Collaborative Research NetworkItaly advances the cholera vaccines market through academic research, vaccine development partnerships, and public health collaboration. Italian institutions continue supporting projects that improve vaccine production processes and strengthen preparedness for infectious disease management.
Japan 🇯🇵
Public Health PreparednessJapan prioritizes vaccine development technologies and preparedness strategies that strengthen responses to infectious disease risks. Japan also supports cholera vaccine research through partnerships focused on improving formulation quality and supply reliability for international health programs.
South Korea 🇰🇷
Biopharmaceutical ExpansionSouth Korea is strengthening its cholera vaccines market through investments in modern vaccine manufacturing infrastructure and biotechnology capabilities. South Korean companies continue expanding production expertise while supporting regional and global vaccine supply partnerships.
United States 🇺🇸
Global Supply InnovationThe U.S. emphasizes vaccine research, manufacturing capacity, and international procurement partnerships that support cholera immunization programs. U.S.-based organizations continue to prioritize product innovation and scalable production for public health and humanitarian vaccination initiatives.
Segment Leadership and Growth Trends
Cholera Vaccines Market Share (%), Type, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportKilled Oral O1 and O139 held a 63% share of the cholera vaccines market in 2025, reflecting its established role in cholera prevention programs and its continued commercial momentum. Its leadership is supported by the practical fit of oral vaccine delivery in large-scale immunization settings, where ease of administration and deployment efficiency matter directly to public health operations. The same operational advantages are also sustaining its faster growth in the cholera vaccines market, as vaccination efforts continue to favor formats that can be used efficiently across target populations while covering the relevant serogroups addressed by this segment.
Distribution Channel Segment Analysis: Hospital Pharmacy (Largest Segment) vs Retail Pharmacy (Fastest-Growing Segment)
Hospital Pharmacy accounted for a 48.23% share of the cholera vaccines market in 2025, making it the leading distribution channel. This position is sustained by the central role hospitals play in vaccine handling, supervised administration, and coordination with formal treatment and immunization pathways, especially where cholera prevention is closely linked with institutional healthcare delivery. The hospital setting also supports controlled storage and managed dispensing, which helps preserve its share in the cholera vaccines market.
Retail Pharmacy is emerging as the fastest-growing distribution channel in the cholera vaccines market because it improves access at the community level and fits better with wider vaccine availability outside hospital settings. Its momentum relative to hospital pharmacy is driven mainly by convenience and reach, as retail outlets can serve populations seeking easier points of access for vaccination. As distribution models broaden beyond institution-centered channels, retail pharmacy is experiencing stronger uptake by aligning with more decentralized vaccine access patterns.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type | Whole Cell V. Cholerae O1 with Recombinant B- Subunit, Killed Oral O1 and O139 | Killed Oral O1 and O139 | Killed Oral O1 and O139 |
| Distribution Channel | Hospital Pharmacy, Retail Pharmacy, Other | Hospital Pharmacy | Retail Pharmacy |
| Product | Vaxchora, Dukoral, Shanchol, Others | Dukoral | Vaxchora |
Competitive Landscape and Market Positioning
1. Sanofi S.A. (France)
2. Valneva SE (France)
3. EuBiologics Co. Ltd. (South Korea)
4. Bharat Biotech International Ltd. (India)
5. Serum Institute of India Pvt. Ltd. (India)
6. Emergent BioSolutions Inc. (United States)
7. Incepta Vaccine Ltd. (Bangladesh)
8. Vabiotech (Vietnam)
9. PT Bio Farma (Persero) (Indonesia)
10. Shantha Biotechnics Pvt. Ltd. (India)
The cholera vaccines market is benefiting from increased focus on public health preparedness and vaccine accessibility across high-risk regions. Collaborative research efforts are supporting advancements in vaccine stability, oral delivery systems, and long-term immunity enhancement. Greater emphasis on scalable production and immunization outreach programs is also contributing to stronger market development initiatives.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| EuBiologics | Mar-24 | EuBiologics secured WHO prequalification for its second cholera vaccine manufacturing facility in South Korea, a critical milestone for increasing global production capacity. This expansion, combined with the successful development of the Euvichol-S vaccine, is expected to enhance output volumes and optimize cost structures to address persistent global supply shortages. |
| Bavarian Nordic | Feb-23 | Bavarian Nordic acquired the rights to the Vaxchora cholera vaccine from Emergent BioSolutions. The transaction included the transfer of manufacturing facilities in Bern, Switzerland, and San Diego, California, along with associated personnel. This acquisition significantly alters the competitive landscape by consolidating manufacturing assets and intellectual property under Bavarian Nordic’s global vaccine portfolio. |
| Biovac Institute | Apr-24 | The Biovac Institute initiated clinical trials for South Africa’s first locally manufactured oral cholera vaccine following regulatory approval. This development marks a material step toward regional vaccine self-sufficiency, reducing reliance on imported supply chains and establishing a new manufacturing footprint to address demand within the African continent. |
| Sapigen Biologix | Apr-24 | Sapigen Biologix announced plans to expand its vaccine manufacturing facility in Odisha, India, with a specific focus on producing oral cholera vaccines. The investment is intended to strengthen India's domestic production capabilities, contributing to global supply resilience and diversifying manufacturing centers for critical immunization products. |
| African Union & French Government | Mar-24 | The African Union and the French Government advanced a strategic initiative to foster local vaccine manufacturing across Africa. By focusing on critical vaccines, including cholera, the collaboration aims to structurally reduce dependence on external suppliers, enhance regional manufacturing capacity, and improve long-term supply chain security for the healthcare market. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Cholera Vaccines Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Cholera Vaccines Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchHow much is the cholera vaccines market worth?
What is the anticipated CAGR of the cholera vaccines industry?
How are preventive immunization strategies reshaping procurement in the cholera vaccines market?
Why are global partnerships and production expansion becoming strategically important in the cholera vaccines market?
Why do Killed Oral O1 and O139 vaccines lead the cholera vaccines market?
Why is retail pharmacy the fastest-growing distribution channel in the cholera vaccines market?
Why does North America lead the cholera vaccines market?
How is Asia Pacific driving fastest growth in cholera vaccines market?
What are the key competitors in the cholera vaccines landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization